Long-term drug release from electrospun fibers for in vivo inflammation prevention in the prevention of peritendinous adhesions
Long-term drug release from electrospun fibers for in vivo inflammation prevention in the prevention of peritendinous adhesions
复制标题
从电纺纤维中长期释放药物，用于体内炎症预防，预防腱周粘连。
DOI：
10.1016/j.actbio.2013.03.040
复制
发表时间：
2013-07-01
影响因子：
9.7
通讯作者：
Cui, Wenguo
中科院分区：
文献类型：
--
作者：
Hu, Changmin;Liu, Shen;Cui, Wenguo
物理屏障，如电纺纤维膜，在预防手术后腱周粘连方面可能有用。然而，由屏障材料降解引起的炎症反应仍然是一个主要挑战。以载药改性介孔氧化硅（MMS）和聚乳酸（PLLA）为原料，采用静电纺丝法制备复合纤维膜。采用基于共溶剂的静电纺丝方法，成功地将布洛芬（IBU）负载的MMS均匀地包封在PLLA纤维中。在体外释放试验中，与电纺PLLA IBU纤维膜（在前12 h内释放46%）相比，电纺PLLA MMS IBU复合纤维膜显示出显著较低的初始突释（在前12 h内释放6%）。此外，PLLA MMS IBU的释放时间也显著长于PLLA IBU（100天vs. 20天）。在动物研究中，PLLA IBU和PLLA MMS IBU在植入后4周与单独的PLLA纤维膜相比显示出改善的抗粘连特性和抗炎作用。此外，与植入PLLA IBU和PLLA的动物相比，植入PLLA MMS IBU 8周的动物显示出最低的炎症和最好的恢复，这很可能是由于其长期IBU释放特性。因此，本研究提供了一种平台技术，用于制造具有长期持续药物释放特性的纤维膜，其可作为长期抗炎和抗粘连的新型载体，以防止腱周粘连。(C)2013 Acta Materialia Inc.由爱思唯尔有限公司出版。保留所有权利。
Physical barriers such as electrospun fibrous membranes are potentially useful in preventing peritendinous adhesions after surgery. However, inflammatory responses caused by degradation of barrier materials remain a major challenge. This study aimed to fabricate electrospun composite fibrous membranes based on drug-loaded modified mesoporous silica (MMS) and poly (L-lactic acid) (PLLA). Using a co-solvent-based electrospinning method ibuprofen (IBU)-loaded MMS was successfully and uniformly encapsulated in the PLLA fibers. The electrospun PLLA MMS IBU composite fibrous membranes showed significantly lower initial burst release (6% release in the first 12 h) compared with that of electrospun PLLA IBU fibrous membranes (46% release in the first 12 h) in in vitro release tests. Moreover, the release from PLLA MMS IBU was also for significantly longer than that from PLLA IBU (100 vs. 20 days). In animal studies both PLLA IBU and PLLA MMS IBU showed improved anti-adhesion properties and anti-inflammatory effects compared with PLLA fibrous membrane alone 4 weeks after implantation. Further, animals implanted with PLLA MMS IBU for 8 weeks showed the lowest inflammation and best recovery compared with those implanted with PLLA IBU and PLLA, most likely as a result of its long-term IBU release profile. Therefore, this study provides a platform technique for fabricating fibrous membranes with long-term sustained drug release characteristics which may function as a novel carrier for long-term anti-inflammation and anti-adhesion to prevent peritendinous adhesions. (C) 2013 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.